1. Home
  2. PBYI vs AGD Comparison

PBYI vs AGD Comparison

Compare PBYI & AGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

N/A

Current Price

$7.61

Market Cap

263.4M

Sector

Health Care

ML Signal

N/A

Logo abrdn Global Dynamic Dividend Fund of Beneficial Interest

AGD

abrdn Global Dynamic Dividend Fund of Beneficial Interest

N/A

Current Price

$12.53

Market Cap

309.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
PBYI
AGD
Founded
2010
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
263.4M
309.7M
IPO Year
2011
2006

Fundamental Metrics

Financial Performance
Metric
PBYI
AGD
Price
$7.61
$12.53
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
370.3K
121.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
37.78
N/A
EPS
0.35
N/A
Revenue
$27,685,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.58
$8.46
52 Week High
$7.68
$13.98

Technical Indicators

Market Signals
Indicator
PBYI
AGD
Relative Strength Index (RSI) 69.82 56.50
Support Level $6.32 $11.15
Resistance Level N/A $12.88
Average True Range (ATR) 0.29 0.21
MACD 0.07 -0.01
Stochastic Oscillator 93.89 56.80

Price Performance

Historical Comparison
PBYI
AGD

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest

Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.

Share on Social Networks: